Nasal Vaccines: Global Markets and Pipeline Analysis
Report Scope:
This report examines trends and sales in the global market for nasal vaccines through 2027. Leaders in the industry and their vaccine portfolios, the need for nasal vaccine development, competitive intelligence and regional trends are discussed. The report includes a PESTEL analysis, that forms in part the base data for qualitative analysis and market estimates.
The report examines all forms of nasal vaccines, such as nasal drops or sprays, but excludes intramuscular and oral vaccines. The report discusses nasal vaccines by type, such as live-attenuated, inactivated, protein subunit and viral vectors. The application areas covered include pediatric and adult. Primary care clinics, hospitals, pharmacies and others are the end-user segments covered.
Report Includes:
This report examines trends and sales in the global market for nasal vaccines through 2027. Leaders in the industry and their vaccine portfolios, the need for nasal vaccine development, competitive intelligence and regional trends are discussed. The report includes a PESTEL analysis, that forms in part the base data for qualitative analysis and market estimates.
The report examines all forms of nasal vaccines, such as nasal drops or sprays, but excludes intramuscular and oral vaccines. The report discusses nasal vaccines by type, such as live-attenuated, inactivated, protein subunit and viral vectors. The application areas covered include pediatric and adult. Primary care clinics, hospitals, pharmacies and others are the end-user segments covered.
Report Includes:
- 23 data tables and 27 additional tables
- A comprehensive overview and up-to-date analysis of the global market for nasal vaccines
- Analyses of the global market trends, with historic market revenue data (sales figures) for 2019-2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
- Highlights of the upcoming market opportunities and trends driving and restricting growth of the global nasal vaccines market and its sub-segments, and the major regions and countries involved in market developments
- Estimation of the actual market size and revenue forecast for the global nasal vaccines market in USD millions, and its corresponding market share analysis by vaccine type, dosage form, patient group, end-user, and region
- Discussion of new developments in the nasal vaccines market, underlying clinical trials for all phases and list of vaccines, and their regulatory approvals etc.
- Identification of the major stakeholders and analysis of the competitive landscape based on recent developments, financial performance, and segmental revenues
- Review of the new announcements, approvals, FDA clearances, partnerships and collaborations in the global nasal vaccines market
- Detailed company profiles of the leading industry players, including AstraZeneca plc, BioDiem Ltd., BlueWillow Biologics, Meissa Vaccines Inc., and Serum Institute of India Pvt., Ltd.
CHAPTER 1 INTRODUCTION
1.1 Study Goals and Objectives
1.2 Reasons for Doing this Study
1.3 Scope of Report
1.4 Information Sources
1.5 Methodology
1.6 Geographic Breakdown
1.7 Analyst's Credentials
1.8 BCC Custom Research
1.9 Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 MARKET OVERVIEW
3.1 Nasal Immune Response
3.2 Benefits of Developing Nasal Vaccines
3.3 Market Drivers
3.3.1 Rising Incidence of Respiratory Infections
3.3.2 Cost-Effective Alternative to Mainstream Vaccines
3.3.3 Increased Government Support and Favorable Regulations
3.3.4 Rising Awareness of the Need for Vaccination Programs
3.3.5 R&D for Nasal Vaccines
3.4 Market Restraints
3.4.1 Limited Immunization in Low- and Middle-Income Countries
3.4.2 Technical Drawbacks of Nasal Vaccines
3.5 Market Opportunities
3.5.1 Demand for Innovative Approaches to Combat COVID-19
3.6 PESTEL Analysis
3.7 Reimbursement Scenarios
3.8 Impact of COVID-19 on the Market for Nasal Vaccines
CHAPTER 4 PIPELINE ANALYSIS OF NASAL VACCINES
4.1 Nasal Vaccine Product Pipeline
4.1.1 Product Pipeline, by Clinical Trial Phase
4.1.2 Product Pipeline, by Disease
4.1.3 Product Pipeline, by Vaccine Type
CHAPTER 5 GLOBAL MARKET FOR NASAL VACCINES BY TYPE
5.1 Live-Attenuated Vaccines
5.2 Inactivated Vaccines
5.3 Viral Vector Vaccines
5.4 Protein Subunit Vaccines
CHAPTER 6 GLOBAL MARKET FOR NASAL VACCINES BY DOSAGE FORM
6.1 Nasal Sprays
6.2 Nasal Drops
6.3 Nasal Powders
6.4 Nasal Gels
CHAPTER 7 GLOBAL MARKET FOR NASAL VACCINES BY PATIENT GROUP
7.1 Pediatric
7.2 Adult
CHAPTER 8 GLOBAL MARKET FOR NASAL VACCINES BY END USER
8.1 Primary Care Clinics
8.2 Hospitals
8.3 Pharmacies
8.4 Other End Users
CHAPTER 9 GLOBAL MARKET FOR NASAL VACCINES BY REGION
9.1 North America
9.2 Europe
9.3 Asia-Pacific
9.4 Rest of the World (RoW)
CHAPTER 10 COMPETITIVE LANDSCAPE
10.1 Announcements
10.2 Drug Approvals
10.3 Partnerships and Collaborations
CHAPTER 11 COMPANY PROFILES
ASTRAZENECA PLC
BHARAT BIOTECH INTERNATIONAL LTD.
BIODIEM LTD.
BLUEWILLOW BIOLOGICS INC.
CODAGENIX INC.
CHANGCHUN BCHT BIOTECHNOLOGY CO.
CYANVAC LLC
INTRAVACC LLC
MEISSA VACCINES INC.
RAZI VACCINE AND SERUM RESEARCH INSTITUTE
SERUM INSTITUTE OF INDIA PVT. LTD.
1.1 Study Goals and Objectives
1.2 Reasons for Doing this Study
1.3 Scope of Report
1.4 Information Sources
1.5 Methodology
1.6 Geographic Breakdown
1.7 Analyst's Credentials
1.8 BCC Custom Research
1.9 Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 MARKET OVERVIEW
3.1 Nasal Immune Response
3.2 Benefits of Developing Nasal Vaccines
3.3 Market Drivers
3.3.1 Rising Incidence of Respiratory Infections
3.3.2 Cost-Effective Alternative to Mainstream Vaccines
3.3.3 Increased Government Support and Favorable Regulations
3.3.4 Rising Awareness of the Need for Vaccination Programs
3.3.5 R&D for Nasal Vaccines
3.4 Market Restraints
3.4.1 Limited Immunization in Low- and Middle-Income Countries
3.4.2 Technical Drawbacks of Nasal Vaccines
3.5 Market Opportunities
3.5.1 Demand for Innovative Approaches to Combat COVID-19
3.6 PESTEL Analysis
3.7 Reimbursement Scenarios
3.8 Impact of COVID-19 on the Market for Nasal Vaccines
CHAPTER 4 PIPELINE ANALYSIS OF NASAL VACCINES
4.1 Nasal Vaccine Product Pipeline
4.1.1 Product Pipeline, by Clinical Trial Phase
4.1.2 Product Pipeline, by Disease
4.1.3 Product Pipeline, by Vaccine Type
CHAPTER 5 GLOBAL MARKET FOR NASAL VACCINES BY TYPE
5.1 Live-Attenuated Vaccines
5.2 Inactivated Vaccines
5.3 Viral Vector Vaccines
5.4 Protein Subunit Vaccines
CHAPTER 6 GLOBAL MARKET FOR NASAL VACCINES BY DOSAGE FORM
6.1 Nasal Sprays
6.2 Nasal Drops
6.3 Nasal Powders
6.4 Nasal Gels
CHAPTER 7 GLOBAL MARKET FOR NASAL VACCINES BY PATIENT GROUP
7.1 Pediatric
7.2 Adult
CHAPTER 8 GLOBAL MARKET FOR NASAL VACCINES BY END USER
8.1 Primary Care Clinics
8.2 Hospitals
8.3 Pharmacies
8.4 Other End Users
CHAPTER 9 GLOBAL MARKET FOR NASAL VACCINES BY REGION
9.1 North America
9.2 Europe
9.3 Asia-Pacific
9.4 Rest of the World (RoW)
CHAPTER 10 COMPETITIVE LANDSCAPE
10.1 Announcements
10.2 Drug Approvals
10.3 Partnerships and Collaborations
CHAPTER 11 COMPANY PROFILES
ASTRAZENECA PLC
BHARAT BIOTECH INTERNATIONAL LTD.
BIODIEM LTD.
BLUEWILLOW BIOLOGICS INC.
CODAGENIX INC.
CHANGCHUN BCHT BIOTECHNOLOGY CO.
CYANVAC LLC
INTRAVACC LLC
MEISSA VACCINES INC.
RAZI VACCINE AND SERUM RESEARCH INSTITUTE
SERUM INSTITUTE OF INDIA PVT. LTD.
LIST OF TABLES
Summary Table: Global Market for Nasal Vaccines, by Region, Through 2027
Table 1: Impact Analysis of Market Drivers and Restraints
Table 2: Confirmed Cases of COVID-19, by Region, as of September 27, 2022
Table 3: Global Nasal Vaccine Product Pipeline, 2019–2022
Table 4: Global Market for Live-Attenuated Nasal Vaccines, by Region, Through 2027
Table 5: Global Market for Nasal Spray Vaccines, by Region, Through 2027
Table 6: Global Market for Nasal Vaccines, by Patient Group, Through 2027
Table 7: Global Market for Pediatric Nasal Vaccines, by Region, Through 2027
Table 8: Global Market for Adult Nasal Vaccines, by Region, Through 2027
Table 9: Global Market for Nasal Vaccines, by End User, Through 2027
Table 10: Global Market for Nasal Vaccines in Primary Care Clinics, by Region, Through 2027
Table 11: Global Market for Nasal Vaccines in Hospitals, by Region, Through 2027
Table 12: Global Market for Nasal Vaccines in Pharmacies, by Region, Through 2027
Table 13: Global Market for Nasal Vaccines for Other End Users, by Region, Through 2027
Table 14: North American Market for Nasal Vaccines, by Patient Group, Through 2027
Table 15: North American Market for Nasal Vaccines, by End User, Through 2027
Table 16: European Market for Nasal Vaccines, by Patient Group, Through 2027
Table 17: European Market for Nasal Vaccines, by End User, Through 2027
Table 18: Asia-Pacific Market for Nasal Vaccines, by Patient Group, Through 2027
Table 19: Asia-Pacific Market for Nasal Vaccines, by End User, Through 2027
Table 20: Rest of the World Market for Nasal Vaccines, by Patient Group, Through 2027
Table 21: Rest of the World Market for Nasal Vaccines, by End User, Through 2027
Table 22: Announcements in the Global Nasal Vaccines Market, 2020–2022
Table 23: Recent Drug Approvals in the Global Nasal Vaccines Market, 2021–2022
Table 24: Partnerships and Collaborations in the Global Nasal Vaccines Market, 2020–2021
Table 25: AstraZeneca: Vaccine Portfolio
Table 26: AstraZeneca: Financial Performance, 2019-2021
Table 27: AstraZeneca: Recent Developments, 2022
Table 28: Bharat Biotech: Vaccine Portfolio
Table 29: Bharat Biotech: Recent Developments, 2022
Table 30: BioDiem Ltd.: Vaccine Portfolio
Table 31: BioDiem Ltd.: Financial Performance, 2019–2021
Table 32: BioDiem Ltd.: Recent Developments, 2020–2021
Table 33: BlueWillow Biologics Inc.: Vaccine Development Programs
Table 34: BlueWillow Biologics Inc.: Recent Developments, 2019–2022
Table 35: Codagenix Inc.: Vaccine Portfolio
Table 36: Codagenix Inc.: Recent Developments, 2020–2022
Table 37: BCHT: Vaccine Portfolio
Table 38: BCHT: Recent Developments, 2021
Table 39: CyanVac LLC: Vaccine Portfolio
Table 40: CyanVac LLC: Recent Developments, 2021–2022
Table 41: Intravacc LLC: Vaccine Portfolio
Table 42: Intravacc LLC: Financial Performance, 2019–2021
Table 43: Intravacc: Recent Developments, 2022
Table 44: Meissa Vaccines Inc.: Vaccine Portfolio
Table 45: Meissa Vaccines Inc.: Recent Developments, 2020–2022
Table 46: Razi Vaccines: Vaccine Portfolio
Table 47: Razi Vaccines: Recent Developments, 2021
Table 48: Serum Institute of India: Vaccine Portfolio
Table 49: Serum Institute of India: Recent Developments, 2020–2021
Summary Table: Global Market for Nasal Vaccines, by Region, Through 2027
Table 1: Impact Analysis of Market Drivers and Restraints
Table 2: Confirmed Cases of COVID-19, by Region, as of September 27, 2022
Table 3: Global Nasal Vaccine Product Pipeline, 2019–2022
Table 4: Global Market for Live-Attenuated Nasal Vaccines, by Region, Through 2027
Table 5: Global Market for Nasal Spray Vaccines, by Region, Through 2027
Table 6: Global Market for Nasal Vaccines, by Patient Group, Through 2027
Table 7: Global Market for Pediatric Nasal Vaccines, by Region, Through 2027
Table 8: Global Market for Adult Nasal Vaccines, by Region, Through 2027
Table 9: Global Market for Nasal Vaccines, by End User, Through 2027
Table 10: Global Market for Nasal Vaccines in Primary Care Clinics, by Region, Through 2027
Table 11: Global Market for Nasal Vaccines in Hospitals, by Region, Through 2027
Table 12: Global Market for Nasal Vaccines in Pharmacies, by Region, Through 2027
Table 13: Global Market for Nasal Vaccines for Other End Users, by Region, Through 2027
Table 14: North American Market for Nasal Vaccines, by Patient Group, Through 2027
Table 15: North American Market for Nasal Vaccines, by End User, Through 2027
Table 16: European Market for Nasal Vaccines, by Patient Group, Through 2027
Table 17: European Market for Nasal Vaccines, by End User, Through 2027
Table 18: Asia-Pacific Market for Nasal Vaccines, by Patient Group, Through 2027
Table 19: Asia-Pacific Market for Nasal Vaccines, by End User, Through 2027
Table 20: Rest of the World Market for Nasal Vaccines, by Patient Group, Through 2027
Table 21: Rest of the World Market for Nasal Vaccines, by End User, Through 2027
Table 22: Announcements in the Global Nasal Vaccines Market, 2020–2022
Table 23: Recent Drug Approvals in the Global Nasal Vaccines Market, 2021–2022
Table 24: Partnerships and Collaborations in the Global Nasal Vaccines Market, 2020–2021
Table 25: AstraZeneca: Vaccine Portfolio
Table 26: AstraZeneca: Financial Performance, 2019-2021
Table 27: AstraZeneca: Recent Developments, 2022
Table 28: Bharat Biotech: Vaccine Portfolio
Table 29: Bharat Biotech: Recent Developments, 2022
Table 30: BioDiem Ltd.: Vaccine Portfolio
Table 31: BioDiem Ltd.: Financial Performance, 2019–2021
Table 32: BioDiem Ltd.: Recent Developments, 2020–2021
Table 33: BlueWillow Biologics Inc.: Vaccine Development Programs
Table 34: BlueWillow Biologics Inc.: Recent Developments, 2019–2022
Table 35: Codagenix Inc.: Vaccine Portfolio
Table 36: Codagenix Inc.: Recent Developments, 2020–2022
Table 37: BCHT: Vaccine Portfolio
Table 38: BCHT: Recent Developments, 2021
Table 39: CyanVac LLC: Vaccine Portfolio
Table 40: CyanVac LLC: Recent Developments, 2021–2022
Table 41: Intravacc LLC: Vaccine Portfolio
Table 42: Intravacc LLC: Financial Performance, 2019–2021
Table 43: Intravacc: Recent Developments, 2022
Table 44: Meissa Vaccines Inc.: Vaccine Portfolio
Table 45: Meissa Vaccines Inc.: Recent Developments, 2020–2022
Table 46: Razi Vaccines: Vaccine Portfolio
Table 47: Razi Vaccines: Recent Developments, 2021
Table 48: Serum Institute of India: Vaccine Portfolio
Table 49: Serum Institute of India: Recent Developments, 2020–2021
LIST OF FIGURES
Summary Figure A: Global Market for Nasal Vaccines, by Region, 2022 and 2027
Summary Figure B: Pipeline Analysis of Nasal Vaccines, by Clinical Trial Phase, 2019–2022
Figure 1: PESTEL Analysis of the Nasal Vaccine Market
Figure 2: Distribution Share of Nasal Vaccine Product Pipeline, by Clinical Trial Phase, 2019–2022
Figure 3: Distribution Share of Nasal Vaccine Product Pipeline, by Disease, 2019–2022
Figure 4: Distribution Share of Nasal Vaccine Product Pipeline, by Vaccine Type, 2019–2022
Figure 5: Global Market Shares of Live-Attenuated Nasal Vaccines, by Region, 2022
Figure 6: Global Market for Live-Attenuated Nasal Vaccines, 2019–2027
Figure 7: Global Market Shares of Nasal Spray Vaccines, by Region, 2022 and 2027
Figure 8: Global Market Shares of Nasal Vaccines, by Patient Group, 2022
Figure 9: Global Market for Nasal Vaccines, by End User, 2022 and 2027
Figure 10: Snapshot of the Global Market Shares of Nasal Vaccines, by Region, 2022
Figure 11: North American Market for Nasal Vaccines, 2019–2027
Figure 12: European Market for Nasal Vaccines, 2019–2027
Figure 13: Asia-Pacific Market for Nasal Vaccines, 2019–2027
Figure 14: Rest of the World Market for Nasal Vaccines, 2019–2027
Figure 15: Global Market Shares of Nasal Vaccines, by Key Strategies Adopted, 2020–2022
Figure 16: AstraZeneca: Annual Revenue, 2019–2021
Figure 17: AstraZeneca: Total Sales Share, by Segment, 2021
Figure 18: AstraZeneca: Total Revenue Share, by Region, 2021
Summary Figure A: Global Market for Nasal Vaccines, by Region, 2022 and 2027
Summary Figure B: Pipeline Analysis of Nasal Vaccines, by Clinical Trial Phase, 2019–2022
Figure 1: PESTEL Analysis of the Nasal Vaccine Market
Figure 2: Distribution Share of Nasal Vaccine Product Pipeline, by Clinical Trial Phase, 2019–2022
Figure 3: Distribution Share of Nasal Vaccine Product Pipeline, by Disease, 2019–2022
Figure 4: Distribution Share of Nasal Vaccine Product Pipeline, by Vaccine Type, 2019–2022
Figure 5: Global Market Shares of Live-Attenuated Nasal Vaccines, by Region, 2022
Figure 6: Global Market for Live-Attenuated Nasal Vaccines, 2019–2027
Figure 7: Global Market Shares of Nasal Spray Vaccines, by Region, 2022 and 2027
Figure 8: Global Market Shares of Nasal Vaccines, by Patient Group, 2022
Figure 9: Global Market for Nasal Vaccines, by End User, 2022 and 2027
Figure 10: Snapshot of the Global Market Shares of Nasal Vaccines, by Region, 2022
Figure 11: North American Market for Nasal Vaccines, 2019–2027
Figure 12: European Market for Nasal Vaccines, 2019–2027
Figure 13: Asia-Pacific Market for Nasal Vaccines, 2019–2027
Figure 14: Rest of the World Market for Nasal Vaccines, 2019–2027
Figure 15: Global Market Shares of Nasal Vaccines, by Key Strategies Adopted, 2020–2022
Figure 16: AstraZeneca: Annual Revenue, 2019–2021
Figure 17: AstraZeneca: Total Sales Share, by Segment, 2021
Figure 18: AstraZeneca: Total Revenue Share, by Region, 2021
